Table 2.
Parameter assumptions for Tiljala and Narkeldanga neighbourhoods of Kolkata, India
| Site characteristics | Base case value | Uncertainty range | Source |
|---|---|---|---|
| Total population (Tiljala and Narkeldanga) | 185,000 | 24 | |
| Children aged <1 year | 2 | 24 | |
| Children aged 1–4 year(s) (% of population) | 7 | 24 | |
| Children aged 5–14 years (% of population) | 20 | 24 | |
| Adults aged 15+ years (% of population) | 72 | 24 | |
| Epidemiology | |||
| Incidence per 1,000: children aged 0–1.9 year(s) | 0.9 | 0.16–5.0 | 19 |
| Incidence per 1,000: children aged 2–4.9 years | 3.4 | 1.9–6.3 | 19 |
| Incidence per 1,000: children aged 5–14.9 years | 4.9 | 4.0–6.7 | 19 |
| Incidence per 1,000: adults aged 15+ years | 1.2 | 0.94–1.6 | 19 |
| Blood culture sensitivity multiplier | 2 | 19 | |
| Case-fatality rate (%) | 1.0 | 0.5–3 | 4,5,21 |
| DALY weight | 0.27 | 0.08–0.47 | See text, 23 |
| Average duration (days) of case | 7 | 4–21 | 4 |
| Vaccine characteristics and costs | |||
| Effectiveness (%) | 65 | 55–75 | 9,10 |
| Duration (years) | 3 | 9,10 | |
| Manufacturing cost (US$) per dose | 0.57 | 0.4–0.8 | Lauria and Stewart |
| Delivery cost (US$) per dose | 0.50 | 0.3–2.5 | Lauria and Stewart |
| Travel/time cost (US$) per dose | 0.06 | Author's calculation | |
| Cost-of-illness (US$) | |||
| Private COI children aged <15 years | 11.7 | 6–18 | Poulos et al. |
| Private COI adults aged >15 years | 11.7 | 6–18 | Poulos et al. |
| Public COI children aged <15 years | 4.3 | 2–6 | Poulos et al. |
| Public COI adults aged >15 years | 4.3 | 2–6 | Poulos et al. |
| Demand/benefit measures | |||
| % who would take if free: children aged 2–4 years | 73 | 58–88 | 25 |
| % who would take if free: children aged 5–14 years | 69 | 55–83 | 25 |
| % who would take if free: adults aged 15+ years | 62 | 50–74 | 25 |
| Slope of demand curve: children aged 2–4 years | −0.14 | −0.11 to −0.17 | 25 |
| Slope of demand curve: children aged 5–14 years | −0.27 | −0.21 to −0.32 | 25 |
| Slope of demand curve: children aged 15+ years | −0.28 | −0.22 to −0.34 | 25 |
| Per vaccine WTP (US$): children aged 2–4 years | 5.2 | 4.2–6.3 | 25 |
| Per vaccine WTP (US$): children aged 5–14 years | 2.6 | 2.1–3.1 | 25 |
| Per vaccine WTP (US$): adults aged 15+ years | 2.2 | 1.8–2.7 | 25 |
| Other parameters | |||
| % of population who hear of programme | 80 | 26,27 | |
| School enrollment rate (%) | 69 | 28 | |
| Discount rate (%) | 3 | 29 | |
| VSL (US$) young children (aged <5 years) | 50,000 | 25k-75k | 30, Maskery et al. |
| VSL (US$) school-age children (aged 5–14 years) | 50,000 | 25k-75k | 30, Maskery et al. |
| VSL (US$) adults (aged 15+ years) | 50,000 | 25k-75k | 30, Maskery et al. |
All currency values are in US$ as of 2007, translated from local currency using market exchange rates
COI=Cost-of-illness; DALY=Disability-adjusted life-year; VSL=Value-of-statistical-life; WTP=Willingness-to-pay
References for Lauria and Stewart, Poulos et al., and Maskery et al. are provided in the body of the text